10 documents

Read All
07:00 , Sep 15, 2014 |  BC Week In Review  |  Company News

Pfizer, Astellas deal

The pharmas agreed to terminate on March 31, 2015, a 2009 deal to co-commercialize Caduet amlodipine besylate/atorvastatin for hypertension and hypercholesterolemia in Japan. Pfizer will be responsible for sole promotion of the product from Oct....
Read More
08:00 , Dec 12, 2011 |  BC Week In Review  |  Company News

Pfizer, Ranbaxy sales and marketing update

Ranbaxy's Ranbaxy Laboratories Ltd. subsidiary launched an authorized generic version of Pfizer's Caduet amlodipine besylate/atorvastatin in the U.S. The hypertension and hypercholesterolemia drug combines hypertension drug Norvasc amlodipine besylate and cholesterol drug Lipitor atorvastatin. The...
Read More
07:00 , Mar 23, 2009 |  BC Week In Review  |  Clinical News

Advicor extended release lovastatin/niacin data

In a retrospective, post-marketing analysis of 6,574 adults taking corticosteroids for asthma, patients who also received statin treatment for a cardiovascular condition had a lower rate of hospitalization or ER visit for asthma over 12...
Read More
07:00 , Jun 23, 2008 |  BC Week In Review  |  Company News

Pfizer, Ranbaxy cardiovascular, metabolic, genitourinary news

The companies settled most of their worldwide patent litigation for Pfizer’s cholesterol drug Lipitor atorvastatin and its hypertension and hypercholesterolemia drug Caduet amlodipine/atorvastatin. Pfizer will grant Ranbaxy rights to market generic atorvastatin in the U.S....
Read More
07:00 , Jun 26, 2006 |  BioCentury  |  Strategy

Statin landscape

Statin landscape On-patent statins Company Product 2005 sales 1Q06 sales Projected sales Cost/day (dose) (B) LDL reduction (C) AstraZeneca/ Shionogi Crestor rosuvastatin $1,268M $387M $1.7B (06), $2.1B (07), $2.5B (08), $2.8B (09), $3.2B (2010) (A)...
Read More
07:00 , Jun 19, 2006 |  BC Week In Review  |  Clinical News

Caduet amlodipine besylate/atorvastatin calcium cardiovascular data

Data from the open-label, European JEWEL II study in 1,107 patients showed that 50.6% of patients achieved country-specific BP and LDL-C goals after 16 weeks. Combined data from JEWEL I and JEWEL II showed that...
Read More
07:00 , Jun 19, 2006 |  BC Week In Review  |  Clinical News

Caduet amlodipine besylate/atorvastatin calcium cardiovascular data

Data from the open-label, U.K. and Canadian JEWEL I study in 1,138 patients showed that 62.9% achieved country-specific BP and LDL-C goals after 16 weeks. Combined data from JEWEL I and JEWEL II showed that...
Read More
07:00 , Jun 28, 2004 |  BC Week In Review  |  Company News

Pfizer sales and marketing update

PFE launched in the U.S. its Caduet amlodipine besylate/atorvastatin calcium to treat hypertension and hypercholesterolemia. Caduet was approved in February and combines hypertension drug Norvasc amlodipine besylate and cholesterol drug Lipitor atorvastatin. Pfizer Inc. (PFE),...
Read More
08:00 , Feb 9, 2004 |  BC Week In Review  |  Clinical News

Caduet amlodipine besylate/atorvastatin calcium regulatory update

FDA granted marketing approval for Caduet to treat hypertension and hypercholesterolemia. Caduet combines hypertension drug Norvasc amlodipine besylate and cholesterol drug Lipitor atorvastatin, and will be available in multiple dosing combinations. Last November, FDA granted...
Read More
08:00 , Feb 2, 2004 |  BC Extra  |  Company News

FDA approves Pfizer's Caduet

The FDA granted marketing approval to PFE for its Caduet amlodipine/atorvastatin to treat hypertension and hypercholesterolemia. Caduet combines PFE's Norvasc amlodipine hypertension drug and its Lipitor atorvastatin cholesterol drug....
Read More